All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the MDS Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, Should novel agents be used prior to transplant in MDS-EB1/2?
Should novel agents be used prior to transplant in MDS-EB1/2?
In this video, Platzbecker discusses whether high-risk MDS patients with excess blasts should be treated with novel agents prior to allogenic stem cell transplantation. Platzbecker also discusses the use of combination therapy.
DRSS: A new disease risk stratification system for hematologic malignancies
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and remission status before transplant. Evaluating...
What are the new approaches for anemia treatment in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Uwe...
Subscribe to get the best content related to MDS delivered to your inbox